Depixus Raises Eur 30.6M (Usd 35.4M) In Series A Financing
12/15/21, 3:00 AM
Location
parisMoney raised
€30.6 million
Round Type
series a
Depixus®, a biotechnology company developing a unique technology for the fast, accurate, and straightforward extraction of multiomic information from DNA, RNA, and proteins, today announces it has raised EUR 30.6 million in an oversubscribed Series A financing. The funds will be used to further develop its proprietary MAGNATM instrument system, workflows, and reagents towards commercial launch. The round was co-led by Lansdowne Partners and the PSIM Fund operated by Bpifrance on behalf of the French State, with participation by Casdin Capital, and existing investors, including Arix Bioscience. This financing brings the company's total equity and grant funding to-date to over EUR 41 million (USD 47 million).
Company Info
Location
paris, ile de france, france
Additional Info
Having seen the impact of methylation detection on liquid biopsy, I look forward to the company making sizeable contributions across the wider dynamic genomics landscape". The firm manages assets for a diversified client base that includes some of the world's largest and most sophisticated investors. About Depixus® and MAGNA™Depixus® is a fast-growing innovative biotechnology company based in Paris, France, and Cambridge, UK, developing its cutting-edge MAGNA™ technology to reveal the secrets of the dynamic genome. Depixus® is a spin-out from spin-out from Ecole Normale Supérieure (ENS), one of the most prestigious 'grandes écoles' in France.